| Hans-Günter Meyer-Thompson | Hepatitiden
HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriers.
HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriers.
Jiang N, Bruneau J, Makarenko I, Minoyan N, Zang G, Høj SB, Larney S, Martel-Laferrière V.
Int J Drug Policy. 2023 Feb 7;113:103954. doi: 10.1016/j.drugpo.2023.103954. Epub ahead of print. PMID: 36758334.
https://www.sciencedirect.com/science/article/pii/S0955395923000038